SMT201400165B - Composizioni e metodi per il trattamento di sclerosi multipla - Google Patents
Composizioni e metodi per il trattamento di sclerosi multiplaInfo
- Publication number
- SMT201400165B SMT201400165B SM201400165T SM201400165T SMT201400165B SM T201400165 B SMT201400165 B SM T201400165B SM 201400165 T SM201400165 T SM 201400165T SM 201400165 T SM201400165 T SM 201400165T SM T201400165 B SMT201400165 B SM T201400165B
- Authority
- SM
- San Marino
- Prior art keywords
- compositions
- treatment
- methods
- multiple sclerosis
- sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| PCT/NZ2010/000112 WO2010147484A1 (fr) | 2009-06-16 | 2010-06-16 | Compositions et procédés pour le traitement de la sclérose en plaques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201400165B true SMT201400165B (it) | 2015-01-15 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201400165T SMT201400165B (it) | 2009-06-16 | 2014-11-04 | Composizioni e metodi per il trattamento di sclerosi multipla |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (fr) |
| EP (1) | EP2442832B1 (fr) |
| JP (1) | JP5646617B2 (fr) |
| CN (1) | CN102458476B (fr) |
| AU (1) | AU2010260585B2 (fr) |
| BR (1) | BRPI1009606A2 (fr) |
| CA (1) | CA2688766C (fr) |
| CY (1) | CY1115714T1 (fr) |
| DK (1) | DK2442832T3 (fr) |
| ES (1) | ES2521565T3 (fr) |
| HK (1) | HK1167101A1 (fr) |
| HR (1) | HRP20141035T1 (fr) |
| IL (1) | IL216993A (fr) |
| IN (1) | IN2012DN00167A (fr) |
| MX (1) | MX2011013661A (fr) |
| NZ (1) | NZ577731A (fr) |
| PL (1) | PL2442832T3 (fr) |
| PT (1) | PT2442832E (fr) |
| SI (1) | SI2442832T1 (fr) |
| SM (1) | SMT201400165B (fr) |
| WO (1) | WO2010147484A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5569944B2 (ja) * | 2008-04-01 | 2014-08-13 | イネイト・イムノセラピューティクス・リミテッド | 抗感染薬およびその使用 |
| LT3326645T (lt) | 2010-10-25 | 2020-08-10 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2017059486A1 (fr) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions et méthodes de traitement de l'épilepsie |
| KR20170041116A (ko) * | 2015-10-06 | 2017-04-14 | 이네이트 이뮤노테라퓨틱스 리미티드 | 신경계의 보호 및/또는 복구용 조성물 및 방법 |
| WO2017070731A1 (fr) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions et méthodes pour le traitement de la maladie d'alzheimer |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| WO2019218079A1 (fr) * | 2018-05-18 | 2019-11-21 | Universite Laval | Utilisation d'un agoniste de nod2 pour le traitement, la prophylaxie et/ou le retardement de l'apparition de la sclérose en plaques et de la maladie d'alzheimer |
| US20210169904A1 (en) * | 2018-07-03 | 2021-06-10 | University Of Florida Research Foundation, Incorporated | Microparticle systems and their use for the treatment of multiple sclerosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU732809B2 (en) * | 1996-10-10 | 2001-05-03 | Innate Immunotherapeutics Limited | Compositions and methods for treating viral infections |
| AU2005259726A1 (en) * | 2004-07-01 | 2006-01-12 | Kobenhavns Universitet | Method for multiple sclerosis treatment and prophylaxis by treatment of Leptospira infection |
| WO2008070564A1 (fr) | 2006-12-01 | 2008-06-12 | The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services | Utilisations du dipeptide muramyle (mdp) dans le traitement de l'inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150182A1 (fr) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions et procédés de traitement de l'anthrax |
| WO2008150181A1 (fr) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions et procédés de traitement des états pathologiques liés à l'exposition au charbon |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/fr not_active Expired - Fee Related
-
2010
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/fr active Active
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/fr active Application Filing
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2012
- 2012-08-10 HK HK12107888.6A patent/HK1167101A1/xx not_active IP Right Cessation
-
2014
- 2014-10-27 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2442832T3 (da) | 2014-11-10 |
| CY1115714T1 (el) | 2017-01-25 |
| MX2011013661A (es) | 2012-05-22 |
| AU2010260585B2 (en) | 2013-02-21 |
| US20100317589A1 (en) | 2010-12-16 |
| CN102458476A (zh) | 2012-05-16 |
| AU2010260585A8 (en) | 2012-06-14 |
| SI2442832T1 (sl) | 2014-12-31 |
| JP5646617B2 (ja) | 2014-12-24 |
| PL2442832T3 (pl) | 2015-01-30 |
| HK1167101A1 (en) | 2013-02-01 |
| WO2010147484A8 (fr) | 2012-07-19 |
| EP2442832A1 (fr) | 2012-04-25 |
| WO2010147484A1 (fr) | 2010-12-23 |
| CN102458476B (zh) | 2014-08-20 |
| IL216993A0 (en) | 2012-02-29 |
| BRPI1009606A2 (pt) | 2016-10-11 |
| JP2012530132A (ja) | 2012-11-29 |
| EP2442832A4 (fr) | 2013-07-03 |
| CA2688766C (fr) | 2015-06-30 |
| PT2442832E (pt) | 2014-11-11 |
| AU2010260585A1 (en) | 2012-01-19 |
| NZ577731A (en) | 2010-08-27 |
| ES2521565T3 (es) | 2014-11-12 |
| EP2442832B1 (fr) | 2014-08-06 |
| IN2012DN00167A (fr) | 2015-04-17 |
| HRP20141035T1 (hr) | 2014-12-19 |
| US8389479B2 (en) | 2013-03-05 |
| CA2688766A1 (fr) | 2010-12-16 |
| IL216993A (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263729A (en) | Preparations and methods for removing biofilms | |
| IL252699A0 (en) | Use of lequinimod to treat multiple sclerosis | |
| SMT201400160B (it) | Nuove composizioni per il trattamento di cmt e malattie correlate | |
| SMT201700036B (it) | Composti e composizioni come inibitori di protein chinasi | |
| SMT201600254B (it) | Procedimento per la preparazione di idromagnesite | |
| SMT201400165B (it) | Composizioni e metodi per il trattamento di sclerosi multipla | |
| SMAP200900085A (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative | |
| BRPI1011587A2 (pt) | compostos e composições terapèuticas | |
| LT3378862T (lt) | Dihidropirimidinoizochinolinonai ir jų farmacinės kompozicijos, skirti išsėtinės sklerozės gydymui | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
| BRPI0911612A2 (pt) | composições e métodos para o tratamento da esclerose múltipla. | |
| HK1166305A1 (zh) | 用於治療炎症的組合物及方法 | |
| SMT201500281B (it) | Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari | |
| SMT201600332B (it) | Composizioni e metodi per l’aumento dell’attivitàtelomerasica | |
| GB0919097D0 (en) | Treatment of hard surfaces | |
| IT1403587B1 (it) | Composizione per il trattamento di disordini metabolici | |
| BRPI0914139A2 (pt) | composições pediátricas para o tratamento de esclerose múltipla | |
| IT1403064B1 (it) | Composizione di sostanze per il trattamento di pazienti con ipercolesterolemia e patologie collegate | |
| EP2560659A4 (fr) | Compositions et méthode utilisées pour le traitement du myélome multiple | |
| GB0808326D0 (en) | Compositions and methods for the treatment of fybromyalgia | |
| IT1403250B1 (it) | Macroapparato per la produzione e il trattamento di gas | |
| IT1398273B1 (it) | Procedimento per la preparazione di 14-bromo daunomicina | |
| GB0921929D0 (en) | Compositions and methods for the treatment of influenza | |
| IT1402253B1 (it) | Impianto e procedimento per il trattamento di reflui inquinanti | |
| IT1403462B1 (it) | Procedimento per la realizzazione di mobili bombati |